Merck & Co. Inc. (MRK)
NYSE: MRK
· Real-Time Price · USD
81.73
1.41 (1.75%)
At close: Jun 12, 2025, 3:59 PM
81.50
-0.28%
After-hours: Jun 12, 2025, 07:59 PM EDT
1.75% (1D)
Bid | 81.01 |
Market Cap | 205.23B |
Revenue (ttm) | 63.92B |
Net Income (ttm) | 17.43B |
EPS (ttm) | 7.05 |
PE Ratio (ttm) | 11.59 |
Forward PE | 8.37 |
Analyst | Hold |
Ask | 82 |
Volume | 8,775,873 |
Avg. Volume (20D) | 16,191,836 |
Open | 80.35 |
Previous Close | 80.33 |
Day's Range | 80.07 - 82.11 |
52-Week Range | 73.31 - 134.63 |
Beta | 0.44 |
Analyst Forecast
According to 0 analyst ratings, the average rating for MRK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-4.72%
Merck shares are trading lower. The company highli...
Unlock content with
Pro Subscription
2 months ago
-4.81%
Merck & Company shares are trading lower. The company announced it entered into an exclusive license agreement with Jiangsu Hengrui Pharmaceuticals for HRS-5346.

20 hours ago · businesswire.com
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine CandidateRAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, i...